Zhitong Finance App News, Yifang Biotech (688382.SH) announced that the registered phase III clinical study of nomelcitinib (D-2570), a novel oral selective inhibitor targeting Tyk2JH2 developed by the company to treat moderate to severe plaque psoriasis, reached a major end point and a key secondary end point. The results of this study mark a milestone in the clinical development of nomelcitinib (D-2570) in the field of psoriasis.

Zhitongcaijing · 11/01 08:17
Zhitong Finance App News, Yifang Biotech (688382.SH) announced that the registered phase III clinical study of nomelcitinib (D-2570), a novel oral selective inhibitor targeting Tyk2JH2 developed by the company to treat moderate to severe plaque psoriasis, reached a major end point and a key secondary end point. The results of this study mark a milestone in the clinical development of nomelcitinib (D-2570) in the field of psoriasis.